Core Viewpoint - The article highlights the rising demand for flu vaccines, antiviral medications, and related testing services due to the increasing flu activity across various regions in China as winter approaches [2][6][8]. Group 1: Flu Vaccine and Antiviral Demand - The flu season is expected to drive significant growth in demand for flu vaccines, respiratory testing, and antiviral medications [2][6]. - Recent data indicates a notable increase in flu vaccine appointments and antiviral drug purchases, with some areas reporting over 500% growth in the number of buyers for antiviral medications [7][8]. - Specific antiviral drugs like Marbofloxacin have seen a remarkable increase in demand, with purchases rising over 600% in recent weeks [7]. Group 2: Market Opportunities - Analysts suggest that the current flu outbreak may lead to heightened public and market interest, creating investment opportunities in flu vaccines, virus testing, and cold medications [8]. - The demand for flu-related products is expected to surge, particularly for antiviral medications such as Oseltamivir and Marbofloxacin, as well as traditional Chinese medicine for flu treatment [8]. - The increase in flu cases is likely to boost the need for diagnostic testing, both in hospitals and for home monitoring, indicating a potential market expansion for testing products [8].

证券代码：688317 证券简称：之江生物 公告编号：2025-066 上海之江生物科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 11 月 25 日（星期二）至 12 月 01 日（星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过上海之江生物科技 股份有限公司（以下简称"公司"）邮箱 info@liferiver.com.cn 进行提问。公 司将在说明会上对投资者普遍关注的问题进行回答。 公司已于 2025 年 10 月 30 日发布公司 2025 年第三季度报告，为便于广大投 资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 12 月 02 日（星期二）09:00-10:00 举行 2025 年第三季度业绩说明会， 就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第三季度的经 营成果及财务 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688317 证券简称：之江生物公告编号：2025-065 上海之江生物科技股份有限公司 关于2025年第三次以集中竞价交易方式回购公司股份的 进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次回购股份符合相关法律法规的规定及公司的回购股份方案。 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号一一回购股 份》等相关规定，在回购期限内根据市场情况择机做出回购决策并予以实施，同时根据回购股份事项进 展情况及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 ■ 一、回购股份的基本情况 2025年10月15日，上海之江生物科技股份有限公司（以下简称"公司"）召开第五届董事会第十六次会 议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》，同意公司以自有资金和股票回 购专项贷款资金通过集中竞价交易方式回购公司部分股份，回购的股份拟用于员工持股计划或股权激 励，回购股份价格不超过人民 ...

Group 1 - The core point of the article is that Zhijiang Biotech has announced a share buyback plan, repurchasing approximately 1.01 million shares, which represents 0.53% of its total share capital of about 192 million shares, with a total expenditure of approximately 22.37 million RMB [1] - The share buyback was conducted through the Shanghai Stock Exchange trading system, with the highest transaction price being 22.86 RMB per share and the lowest at 21.52 RMB per share [1] - For the year 2024, Zhijiang Biotech's revenue composition is heavily weighted towards the in vitro diagnostics industry, accounting for 98.25% of total revenue, while other businesses contribute only 1.75% [1] Group 2 - As of the report, Zhijiang Biotech has a market capitalization of 4.1 billion RMB [2]

证券代码：688317 证券简称：之江生物 公告编号：2025-065 上海之江生物科技股份有限公司 关于2025年第三次以集中竞价交易方式回购公司股份 的进展公告 一、回购股份的基本情况 2025 年 10 月 15 日，上海之江生物科技股份有限公司（以下简称"公司"） 召开第五届董事会第十六次会议，审议通过了《关于以集中竞价交易方式回购公 司股份方案的议案》，同意公司以自有资金和股票回购专项贷款资金通过集中竞价 交易方式回购公司部分股份，回购的股份拟用于员工持股计划或股权激励，回购 股份价格不超过人民币 37.99 元/股（含），回购资金总额不低于人民币 6,000 万 元（含），不超过人民币 12,000 万元（含），回购期限自公司董事会审议通过本次 回购方案之日起 12 个月内。具体内容详见公司于 2025 年 10 月 17 日在上海证券 交易所网站（www.sse.com.cn）披露的《关于 2025 年第三次以集中竞价交易方式 回购股份方案的公告》（公告编号：2025-055）。 二、回购股份的进展情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容 ...

Core Insights - The company, Zhijiang Biology, has been successfully selling multiple diagnostic products to the EU market over the past two years, leveraging its CE certification obtained from the European Union [2] Group 1 - The company has relied on its CE certification to ensure stable sales of its diagnostic products in the EU [2] - The interaction with investors indicates a positive outlook on the company's market performance in Europe [2]

Core Viewpoint - Zhijiang Biotech (stock code: 688317) has received overwhelming support from shareholders to engage in foreign exchange derivative trading to mitigate currency risk associated with its international business operations [1][2]. Group 1: Shareholder Meeting and Approval - The second extraordinary general meeting of Zhijiang Biotech was attended by 112 shareholders, representing approximately 72.82 million shares, or 37.9% of the total share capital [1]. - The proposal to conduct foreign exchange derivative trading was approved with a high vote of 99.52% [1]. - The company plans to engage in foreign exchange derivatives with a limit of up to $20 million (or equivalent in other currencies) within 12 months of the approval [1]. Group 2: Business Strategy and Rationale - The company aims to hedge against currency fluctuations due to its import and export operations, which often involve foreign currencies like the US dollar [1][2]. - Although current overseas revenue is modest at around 2.3 million yuan, the company is in a critical phase of expanding its international presence, including markets like Japan [2]. - Zhijiang Biotech is also exploring overseas acquisition targets to diversify its business strategy [2]. Group 3: Financial Performance - For the first three quarters of the year, Zhijiang Biotech reported revenue of 90.43 million yuan, a year-on-year decline of 34.27%, with a net loss attributable to shareholders of 29.38 million yuan [3]. - Despite the revenue drop, the company increased its R&D investment, which accounted for 46.51% of revenue, up 18.11 percentage points from the previous year [3]. - The company has effectively managed its inventory levels, which have returned to normal after previous adjustments [4]. Group 4: Innovation and Drug Development - Zhijiang Biotech has signed a strategic cooperation agreement with Sanyou Biotech to enhance drug development automation, aiming to shorten R&D cycles and improve efficiency [5]. - The company is focusing on innovative drug development, particularly in infectious diseases and oncology, with ongoing preclinical studies [6][7]. - The company is leveraging its expertise in materials science and chip technology to develop organoid technology for personalized medicine and drug screening [6]. Group 5: Future Plans and Financial Strategy - The company plans to establish an independent platform for innovative drug development, indicating a strategic shift towards this area [7]. - Zhijiang Biotech is evaluating various projects for investment, with a focus on synergy with its core business [7]. - The company has over 2 billion yuan in cash, which will be strategically utilized for future investments [7].

（文章来源：证券日报） 证券日报网讯之江生物11月17日在互动平台回答投资者提问时表示，截至2025年9月30日，股东总数为 14435户。 ...

证券代码：688317 证券简称：之江生物 公告编号：2025-064 上海之江生物科技股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 11 月 14 日 （二） 股东会召开的地点：上海市闵行区陈行路 2388 号 8 幢 102 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 112 | | --- | --- | | 普通股股东人数 | 112 | | 2、出席会议的股东所持有的表决权数量 | 72,821,903 | | 普通股股东所持有表决权数量 | 72,821,903 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 41.1290 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 41.1290 | （四） ...

法律意见书 浙江天册律师事务所 关于 上海之江生物科技股份有限公司 2025 年第二次临时股东会的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 法律意见书 浙江天册律师事务所 关于上海之江生物科技股份有限公司 2025 年第二次临时股东会的 法律意见书 编号：TCYJS2025H1845 号 致：上海之江生物科技股份有限公司 浙江天册律师事务所（以下简称"本所"）接受上海之江生物科技股份有限 公司（以下简称"之江生物"或"公司"）的委托，指派本所律师参加公司 2025 年第二次临时股东会，并根据《中华人民共和国证券法》（以下简称"《证券 法》"）、《中华人民共和国公司法》（以下简称"《公司法》"）和《上市公 司股东会规则》（以下简称"《股东会规则》"）等法律、法规和其他有关规范 性文件的要求出具本法律意见书。 在本法律意见书中，本所律师仅对本次股东会召集、召开程序、出席人员的 资格、召集人的资格、表决程序及表决结果的合法有效性发表意见，不对会议所 审议的议案内容和该等议案中所表述的事实或数据的真实性和准 ...